Pharmacokinetic testing plays an important role in the pre-clinical trials of pharmaceuticals. It is crucial to understand the ways that this science can help researchers and pharmaceuticals in their efforts to create a better products. This testing is done on animals, but there are many things that can be learned from it. One example of this is to understand how the drug will be processed by the body and what effects it will have.
Pharmacokinetics measures the rate and time the substance is distributed throughout the body. Pharmacokinetic information provides guidance on dose-response relationships between a drug’s concentration and its effect and helps predict drug interactions, adverse reactions, and improved efficacy. This science determines what happens to a drug from the time it is administered throughout its circulation within the body to the moment when it is ultimately eliminated from the body.
The pharmacokinetics testing model is a mathematical standard that is commonly used to understand the concepts of pharmacokinetics testing along with the processes that take place in the body. The multi-compartment model illustrates how certain materials or energies move throughout a system.
When it comes to studying the effects of drugs on the human body, safety is a major concern. This holds true for pharmacology studies, as well. The European Medicines Agency released a health care guideline in April 2018 discussing the importance of ensuring medications are safe to use in humans by analyzing the drug’s effects on cardiovascular, central nervous, and respiratory systems in animal models first.
The safety pharmacology of a drug refers to the risks and potential side effects of using that medication. These tests, also referred to by regulators as toxicological and pharmacological studies should be conducted even when medicine seems safe enough during phase 1 trial testing. The review suggests that researchers conduct in vivo testing along with standard toxicity studies to ensure their drug development efforts are safe, reduce animal use within pre-clinical trials, and ensure the likelihood of approval under their own labeling guidelines.
Researchers must first conduct specifically in vitro studies before they can move forward with human clinical trials. These models may include metabolism and plasma protein binding studies as well as determining systemic exposure data for repeated-dose toxicity studies.
Pharmacokinetic properties of drugs can also be studied in pre-clinical testing, like distribution, absorption, and metabolism. When an animal model is used to study these properties, they must be reported and analyzed before proceeding with human clinical trials.
For drugs with an administration dose of fewer than 10 milligrams, it may be necessary to test a greater amount of the drug material to learn of any adverse reactions. The use of animal models in pre-clinical testing is a common practice and can be very useful. However, the results from these tests are not always transferable to humans. This is because human metabolism differs from that of animals, making it difficult to predict how well a drug will work on people based solely on its performance in animals.
A good pharmacokinetic study can decrease the workload of your drug development by 10 times because you don’t have to conduct any more clinical trials. It is safe, cost-effective, and reliable.
Elisa testing is a powerful tool for identifying the presence of an antigen in a sample, but it does not provide a quantitative real-time measurement.